WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $2.39B | Feb 22, 2013 |
| FY2011 | Dec 31, 2011 | $1.97B | Feb 24, 2012 |
| FY2011 | Dec 31, 2010 | $1.51B | Feb 24, 2012 |
| FY2011 | Dec 31, 2009 | $1.40B | Feb 24, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.17B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $10.39B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $9.68B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $8.36B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $7.82B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $7.56B | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $2.37B | Feb 24, 2020 |
| FY2019 | Sep 30, 2019 | $2.00B | Feb 24, 2020 |
| FY2019 | Jun 30, 2019 | $2.24B | Feb 24, 2020 |
| FY2019 | Mar 31, 2019 | $1.59B | Feb 24, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.08B | Feb 26, 2018 |
| FY2017 | Sep 30, 2017 | $957.93M | Feb 26, 2018 |
| FY2017 | Jun 30, 2017 | $932.25M | Feb 26, 2018 |
| FY2017 | Mar 31, 2017 | $916.03M | Feb 26, 2018 |
| FY2017 | Dec 31, 2016 | $759.98M | Feb 26, 2018 |
| FY2017 | Sep 30, 2016 | $675.57M | Feb 26, 2018 |
| FY2017 | Jun 30, 2016 | $723.60M | Feb 26, 2018 |
| FY2017 | Mar 31, 2016 | $772.03M | Feb 26, 2018 |
| FY2016 | Dec 31, 2015 | $832.85M | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $809.53M | Feb 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.81B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.37B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.94B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.54B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $2.37B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $2.14B | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $674.90M | Feb 24, 2020 |
| FY2019 | Sep 30, 2019 | $599.40M | Feb 24, 2020 |
| FY2019 | Jun 30, 2019 | $614.70M | Feb 24, 2020 |
| FY2019 | Mar 31, 2019 | $389.00M | Feb 24, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $815.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $633.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $558.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $414.00M | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $135.70M | Feb 24, 2020 |
| FY2019 | Sep 30, 2019 | $91.10M | Feb 24, 2020 |
| FY2019 | Jun 30, 2019 | $104.10M | Feb 24, 2020 |
| FY2019 | Mar 31, 2019 | ($4.20M) | Feb 24, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.61B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.27B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.01B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $876.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $745.00M | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $226.10M | Feb 24, 2020 |
| FY2019 | Sep 30, 2019 | $169.10M | Feb 24, 2020 |
| FY2019 | Jun 30, 2019 | $200.60M | Feb 24, 2020 |
| FY2019 | Mar 31, 2019 | $67.30M | Feb 24, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $223.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $206.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $218.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $209.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $176.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $162.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $210.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $87.50M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $95.20M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $71.38M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.25B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.14B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.03B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $1.03B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $948.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.17B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $633.20M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $512.50M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $373.56M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.76B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.83B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.20B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.04B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $1.07B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $784.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.02B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $314.70M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $188.80M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $450.53M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $260.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $207.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $186.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $149.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $130.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $136.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $186.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $93.30M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $89.50M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $50.22M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.07B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $18.70B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $18.99B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $18.52B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $18.45B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $18.45B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $18.94B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $8.65B | Feb 24, 2020 |
| FY2019 | Dec 31, 2017 | $6.58B | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $6.58B | Feb 27, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.88B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $8.57B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $8.46B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $8.37B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $8.22B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $8.30B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $8.95B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $5.78B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $3.75B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $3.60B | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.14B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $10.09B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $10.49B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $10.10B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $10.20B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $10.12B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $9.96B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $2.87B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $2.81B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.21B | Feb 26, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.22B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $8.71B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $8.78B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $8.51B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $8.59B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $8.49B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $8.36B | Feb 17, 2022 |
| FY2019 | Dec 31, 2018 | $2.40B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $2.46B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.08B | Feb 26, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.88B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $6.19B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $5.27B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $4.58B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $4.06B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $3.59B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $3.27B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $3.02B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $2.77B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.55B | Feb 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $473.00M | Feb 17, 2022 |
| FY2021 | Dec 31, 2020 | $599.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $604.20M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $580.90M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $233.40M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $398.48M | Feb 26, 2018 |
| FY2017 | Dec 31, 2015 | $226.19M | Feb 26, 2018 |
| FY2017 | Dec 31, 2014 | $425.85M | Feb 26, 2018 |
| FY2016 | Dec 31, 2013 | $285.76M | Feb 28, 2017 |
| FY2015 | Dec 31, 2012 | $215.77M | Feb 19, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.54B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.98B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $4.07B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $4.00B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $4.06B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $4.24B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $4.43B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $3.86B | Feb 24, 2020 |
| FY2012 | Dec 31, 2012 | $317.90M | Feb 22, 2013 |
| FY2012 | Dec 31, 2011 | $395.87M | Feb 22, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 24, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 24, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 24, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 24, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 24, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 24, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 24, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 24, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 170.60M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 171.30M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | 177.80M | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | 181.20M | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | 185.80M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | 188.90M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 191.70M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | 96.61M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | 96.03M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 95.43M | Feb 26, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $140.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $123.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $111.00M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $92.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $93.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $82.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $46.30M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $42.20M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $32.43M | Feb 27, 2019 |